Literature DB >> 22659961

Clinical and pathological characteristics, outcome and mutational profiles regarding non-small-cell lung cancer related to wood-smoke exposure.

Oscar Arrieta1, Alma D Campos-Parra, Carlos Zuloaga, Alejandro Avilés, Roberto Sánchez-Reyes, María Eugenia Vázquez Manríquez, Emilia Covián-Molina, Luis Martínez-Barrera, Abelardo Meneses, Andrés Cardona, José R Borbolla-Escoboza.   

Abstract

HYPOTHESIS: Although smoking is the major risk factor for non-small-cell lung cancer (NSCLC), other factors are also associated with lung carcinogenesis, such as wood-smoke exposure (WSE). This article has been aimed at suggesting that lung cancer related to cigarette smoking and lung cancer related to WSE have different clinical and genetic characteristics. EXPERIMENTAL
DESIGN: A cohort of 914 lung cancer patients was prospectively studied; they had been treated at Mexico's National Cancer Institute between 2007 and 2010. The associations of WSE and cigarette smoking with clinical characteristics, mutation profile, response to chemotherapy, and epidermal growth factor receptor tyrosine kinase inhibitors were analyzed, and overall survival (OS) rate was calculated. The trial was registered with ClinicalTrials.gov: NCT01023828.
RESULTS: Of the lung cancer patients studied, 95.1% were classified as coming within the NSCLC histology subtype; 58% of the patients smoked cigarettes, 35% had a background of WSE (exposure to both cigarette smoke and wood smoke was documented in 12.1% of all patients), and 19.4% patients had no smoke-exposure background. WSE was associated with NSCLC and adenocarcinoma histology, and was also more frequently associated with epidermal growth factor receptor-mutations than cigarette-smoking patients were (50.0% cf. 19.4%), whereas KRAS mutations were less common in WSE patients (6.7%) than in smokers (21%). WSE patients had a higher epidermal growth factor receptor tyrosine kinase inhibitor response rate (39.7%) than smokers (18.8%). The NSCLC patient WSE group's OS was longer (22.7 months) than that for smokers (13.8 months).
CONCLUSION: NSCLC patients who smoked tobacco/cigarettes differed from those having a background of WSE regarding tumor histology, mutation profile, response rate, and OS, indicating that different carcinogenic mechanisms were induced by these two types of smoke exposure.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22659961     DOI: 10.1097/JTO.0b013e3182582a93

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  18 in total

1.  EGFR Mutation Testing: Changing Patterns of Molecular Testing in Brazil.

Authors:  Sofia Palacio; Luciola Pontes; Edna Prado; Junaid Arshad; Robert Ali; Tony Piha; Carlos Eduardo Bacchi; Raja Mudad; Gilberto Lopes
Journal:  Oncologist       Date:  2018-11-16

2.  Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin-paclitaxel.

Authors:  Oscar Arrieta; Pablo Anaya; Vicente Morales-Oyarvide; Laura Alejandra Ramírez-Tirado; Ana C Polanco
Journal:  Eur J Health Econ       Date:  2015-09-04

3.  Reduction in Hepatocyte Growth Factor Serum Levels is Associated with Improved Prognosis in Advanced Lung Adenocarcinoma Patients Treated with Afatinib: a Phase II Trial.

Authors:  Oscar Arrieta; Graciela Cruz-Rico; Enrique Soto-Perez-de-Celis; Laura-Alejandra Ramírez-Tirado; Enrique Caballe-Perez; Jorge-Negueb Martínez-Hernández; Ivan Martinez-Alvarez; Giovanny Soca-Chafre; Eleazar Omar Macedo-Pérez; Horacio Astudillo-de la Vega
Journal:  Target Oncol       Date:  2016-10       Impact factor: 4.493

Review 4.  Influence of estrogen in non-small cell lung cancer and its clinical implications.

Authors:  Vianey Rodriguez-Lara; Juan-Manuel Hernandez-Martinez; Oscar Arrieta
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

5.  Characteristics of progression to tyrosine kinase inhibitors predict overall survival in patients with advanced non-small cell lung cancer harboring an EGFR mutation.

Authors:  Feliciano Barrón; Andrés F Cardona; Luis Corrales; Laura-Alejandra Ramirez-Tirado; Enrique Caballe-Perez; Gisela Sanchez; Diana Flores-Estrada; Zyanya Lucia Zatarain-Barrón; Oscar Arrieta
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

6.  Mortality Trends for Lung Cancer and Smoking Prevalence In Peru.

Authors:  J Smith Torres-Roman; Bryan Valcarcel; Jose Fabian Martinez-Herrera; Janina Bazalar-Palacios; Carlo La Vecchia; Luis E Raez
Journal:  Asian Pac J Cancer Prev       Date:  2022-02-01

7.  Medical care costs incurred by patients with smoking-related non-small cell lung cancer treated at the National Cancer Institute of Mexico.

Authors:  Oscar Arrieta; Roger Humberto Quintana-Carrillo; Gabriel Ahumada-Curiel; Jose Francisco Corona-Cruz; Elma Correa-Acevedo; Juan Zinser-Sierra; Dolores de la Mata-Moya; Alejandro Mohar-Betancourt; Vicente Morales-Oyarvide; Luz Myriam Reynales-Shigematsu
Journal:  Tob Induc Dis       Date:  2015-02-04       Impact factor: 2.600

Review 8.  An Overview of Lung Cancer in Women and the Impact of Estrogen in Lung Carcinogenesis and Lung Cancer Treatment.

Authors:  Vianey Rodriguez-Lara; Maria Rosa Avila-Costa
Journal:  Front Med (Lausanne)       Date:  2021-05-17

Review 9.  Interplay between Cellular and Molecular Inflammatory Mediators in Lung Cancer.

Authors:  Mario Orozco-Morales; Giovanny Soca-Chafre; Pedro Barrios-Bernal; Norma Hernández-Pedro; Oscar Arrieta
Journal:  Mediators Inflamm       Date:  2016-01-28       Impact factor: 4.711

10.  Gene-expression profiles in lung adenocarcinomas related to chronic wood smoke or tobacco exposure.

Authors:  Alette Ortega-Gómez; Claudia Rangel-Escareño; Camilo Molina-Romero; Eleazar Omar Macedo-Pérez; Alejandro Avilés-Salas; Alejandra Lara-García; Gerardo Alanis-Funes; Rubén Rodríguez-Bautista; Alfredo Hidalgo-Miranda; Oscar Arrieta
Journal:  Respir Res       Date:  2016-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.